USSTOCK.TODAY
Pre-Market
Log in Sign up

Guggenheim names Surrozen top biotech stock following Johnson & Johnson acquisition announcement

Investing.com +1 · ·by G4L

SRZN
SRZN Surrozen Inc
$31.74 +5.87%
View chart & analysis →
  1. 1Johnson & Johnson is acquiring Olin Biosciences for an upfront payment of $2.2 billion.
  2. 2Guggenheim maintains a buy rating on Surrozen and sets a price target of $80.
  3. 3Surrozen recently expanded its Phase 2a clinical study scale.

So what's the key point?

Johnson & Johnson has decided to acquire Olin Biosciences. Guggenheim called Surrozen a top pick and expects its stock to reach $80.

Source Investing.com +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →